Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA

Save

Follow the Money (4.23.2026)

Save

Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week. 

Twofold Mortality in SLE

Save

NSAIDs in Inflammatory Bowel Disease?

Save

At least some patients with inflammatory bowel disease (IBD) can safely use common drugs for musculoskeletal aches and pains, a large study of insurance claims data suggested, contradicting a widespread concern that these products can trigger IBD flares.

ACR Endorses New Training Model for Pediatric Subspecialties

Save

The American College of Rheumatology (ACR) welcomes the recent announcement from the American Board of Pediatrics (ABP) outlining new training models for pediatric subspecialties.

Rheumatology Salaries 2025

Save

Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum. 

Aspirin Cardiovascular Prevention in Giant Cell Arteritis

Save

A retrospective target trial emulations has shown that low-dose aspirin (ASA) given with a giant cell arteritis (GCA) diagnosis is associated with a lower risk of major adverse cardiovascular events (MACE), but a higher risk of GI bleeding.

Weight-loss drugs may affect joints directly

Save

A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis.

Prescribing Lessons (4.17.2026)

Save

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

ACR Backs the Provider Reimbursement Stability Act

Save

The American College of Rheumatology (ACR) today thanked lawmakers in the U.S. House of Representatives for introducing the bipartisan Provider Reimbursement Stability Act of 2025 (H.R. 8163), legislation designed to stabilize Medicare payments for physicians and protect patient access to care.

Adjunctive Prednisolone for Kawasaki Disease

Save

An NEJM study has shown that glucocorticoids provide no added benefit when added to standard primary treatment in Kawasaki disease patients.

Still's Disease Update

Save

Arthritis Research & Therapy has published an overarching review of Still's disease - claiming it to be a single acquired and complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations and clinical presentations, with minor differences between children and adults who are afflicted.